Levetiracetam Arrow Lab

Levetiracetam, the active ingredient in Levetiracetam Arrow Lab, is an antiepileptic presented as an injectable solution for intravenous use. It is employed as adjunctive therapy for partial‑onset, myoclonic, and primary generalized tonic‑clonic seizures in patients who require additional seizure control.

GNH USA supplies Levetiracetam Arrow Lab as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Levetiracetam is an antiepileptic indicated for several seizure types.

Partial‑onset seizures: reduces seizure frequency as adjunctive therapy. Myoclonic seizures: provides adjunctive seizure control. Primary generalized tonic‑clonic seizures: used as adjunctive therapy to decrease seizure occurrence.

Levetiracetam may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Dizziness: transient sensation of light‑headedness. - Somnolence: increased sleepiness or fatigue. - Irritability: mood changes or agitation. - Nausea: mild gastrointestinal upset.

Serious or Rare Side Effects: - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Psychiatric events: depression, suicidal thoughts, or aggressive behaviour. - Hematologic abnormalities: thrombocytopenia or severe allergic reactions.

When using Levetiracetam, several safety considerations are recommended.

Renal impairment: adjust dose based on creatinine clearance. Psychiatric monitoring: watch for new or worsening mood changes. Avoid abrupt discontinuation: taper under medical supervision to prevent seizure exacerbation. Hepatic disease: use with caution in patients with liver dysfunction. Hypersensitivity: discontinue if signs of allergic reaction appear. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Levetiracetam can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Strong enzyme inducers (e.g., carbamazepine, phenytoin): may lower levetiracetam plasma levels. - Other CNS depressants: can increase sedation and respiratory depression. - Drugs associated with severe skin reactions (e.g., lamotrigine): risk of overlapping cutaneous toxicity.

Moderate Interactions (Monitor Closely): - Additional antiepileptics: may necessitate dose adjustments for optimal seizure control. - Anticoagulants: potential increase in bleeding tendency. - Alcohol: may enhance dizziness and somnolence.